Overview of the Turkish pharmaceutical market
Türkiye’s pharmaceutical market presents a compelling opportunity for foreign investors, driven by a combination of robust growth, favorable investment environment, and strategic government support. As of 2024, the global pharmaceutical market has reached a staggering 1.6 trillion USD, with Türkiye ranking 19th globally in this sector source.
The Turkish pharmaceutical market itself has demonstrated significant growth, reaching 211 billion TRY in 2023, with unit sales totaling 2.67 billion units. This growth is underpinned by a strong healthcare system and government initiatives. The Healthcare Transformation Program and Universal Healthcare Insurance, launched in 2003, have ensured free healthcare coverage to 95% of the population, driving demand for pharmaceutical products source.
Market composition and growth sectors
One of the key aspects of the Turkish pharmaceutical market is the balance between originator and generic drugs. As of 2023, originator drugs dominate the market with a 59% share in value and 35% in units, while generic drugs constitute the remainder. This mix indicates a mature market with room for both innovative and cost-effective treatments source.
Biotechnological products are another area of significant growth, constituting 17.6% of prescription products in 2023. The biotechnological pharmaceutical market grew by 84.4% to total 32.2 billion TRY, with biosimilar drugs increasing by 92.2% to reach 5 billion TRY. This rapid expansion is supported by government incentives and the implementation of EU biosimilars guidelines, which allow for fast-track registration and substitution of biosimilars at the pharmacy level source.
Exports and international strategy
The pharmaceutical sector in Türkiye is also characterized by its strong export performance. In 2023, pharmaceutical exports reached $2.23 billion, highlighting the country’s potential as a manufacturing hub for regional markets. Global pharmaceutical companies have been leveraging Türkiye’s strategic location to access nearby markets, further bolstering the sector’s international presence source.
Regulatory and economic environment
Investment in the Turkish pharmaceutical industry is facilitated by a favorable regulatory environment. The government has implemented various support programs, including those under the Technology-Oriented Industry Move Program, aimed at increasing value-added production in sectors like chemistry, pharmacy, and the manufacture of medical and dental equipment. Additionally, the 2023-2025 Pre-Accession Economic Reform Program includes promises to strengthen the supply chain of pharmaceutical and medical supplies through the State Supply Office source.
Challenges and sustainability
However, despite these opportunities, the sector faces several challenges. The high VAT rate of 18% on medicines, which is higher than the European Union average, imposes a significant tax burden. Moreover, the Social Security Institution (SSI) acts as a monopsony in the domestic market, controlling prices and influencing the foreign currency exchange rate for pharmaceutical imports. This can deter global pharmaceutical companies from investing in Türkiye source. To address these issues, the implementation of cost-effective programs in public health care insurance schemes and finding a balance between budget control and market sustainability are crucial.
Demographics and R&D support
Foreign investors are also drawn to Türkiye’s pharmaceutical sector due to its favorable demographics and macroeconomic conditions. The country boasts a dynamic, young, and skilled talent pool, increasing life expectancy, and rising healthcare spending. These factors, combined with strong government support for research and development, create a lucrative environment for investment. For instance, the 12th Development Plan for 2024-2028 designates medicine and biomedical equipment as priority areas, with a focus on biotechnological drugs and vaccines source.
Localization and investment opportunities
The localization program in Türkiye aims to reduce import dependency and increase local production, which presents opportunities for foreign investors to partner with local companies. Successful partnerships can capitalize on local experience and networks, facilitating growth in the region. The example of Gen Ilac, a Turkish pharmaceutical company that successfully conducted an initial public offering (IPO) in 2021, highlights the interest in sustainable development opportunities in the sector. The IPO saw a demand 6.7 times the public offering size, indicating strong investor interest in Turkish pharmaceutical companies source.
Pharmaceutical packaging market potential
The pharmaceutical packaging market in Türkiye is another sector that holds promise. Expected to grow at a CAGR of 7.8% from 2024 to 2030, this market is driven by segments such as plastics & polymers, paper & paperboard, glass, and aluminum foil. Plastics & polymers were the largest revenue-generating material in 2023, with glass being the fastest-growing segment. This growth trajectory indicates opportunities for investors in the packaging sector, which is crucial for the overall pharmaceutical industry source.
Conclusion
For foreign investors considering entry into the Turkish pharmaceutical market, several recommendations are pertinent. First, it is essential to understand the regulatory landscape and the role of the SSI in controlling prices and market dynamics. Building partnerships with local companies can provide valuable insights and networks, facilitating smoother integration into the market. Additionally, leveraging government incentives and support programs can significantly enhance the viability of investments.
In conclusion, the Turkish pharmaceutical market offers a rich tapestry of opportunities for foreign investors. With its robust growth, favorable investment environment, and strategic government support, this sector is poised for continued expansion. Addressing the challenges related to taxation and market sustainability will be crucial for sustaining this growth. As the global pharmaceutical market continues to evolve, Türkiye’s position as a significant player in the “pharmerging” markets makes it an attractive destination for investment in the pharmaceutical industry.